Welcome to our dedicated page for Dermata Therapeutics news (Ticker: DRMAW), a resource for investors and traders seeking the latest updates and insights on Dermata Therapeutics stock.
The Dermata Therapeutics, Inc. (DRMA, DRMAW) news page on Stock Titan aggregates company-issued updates, clinical milestones, financing announcements, and regulatory disclosures related to its dermatology-focused business. Dermata describes itself as a science-driven leader in dermatologic solutions built around its proprietary Spongilla technology platform, with programs in acne, hyperhidrosis, and other skin diseases and aesthetic applications.
Recent news highlights Dermata’s strategic pivot from prescription dermatology development to over-the-counter (OTC) pharmaceutical skin treatments that can be sold directly to consumers. Company press releases and an accompanying Form 8-K explain that Dermata is prioritizing an OTC once-weekly acne kit that combines an active ingredient from the OTC acne monograph with its Spongilla technology, with launch preparations involving branding, packaging, manufacturing, and consumer research.
News items also cover clinical and scientific developments, such as positive topline data from the Phase 3 STAR-1 trial of XYNGARI™ in moderate-to-severe acne, additional data presentations at international dermatology congresses, and collaboration activities around DMT410 for topical botulinum toxin delivery in hyperhidrosis and aesthetic indications. Financing-related releases describe private placements and warrant transactions intended to fund operations and OTC product launch activities, while other notices address Nasdaq listing compliance and corporate actions like a reverse stock split.
Investors and observers can use this news feed to follow Dermata’s progress in OTC dermatology, updates on its Spongilla-based acne kit, developments in its DMT410 program, intellectual property milestones, and material events reported in 8-K filings. Bookmark this page to review Dermata’s historical and ongoing disclosures as it advances its dermatology strategy.
Dermata Therapeutics has successfully closed a private placement, raising $5.0 million through the sale of 3,773,585 shares of common stock and warrants. Each share was sold at a price of $1.325, with warrants exercisable over five years. The net proceeds will be allocated for working capital and corporate purposes. The transaction was facilitated by Maxim Group LLC as the placement agent. Dermata specializes in treatments for skin conditions and is developing its lead product candidate, DMT310, targeting acne and psoriasis.
Dermata Therapeutics announced a private placement agreement to raise approximately $5.0 million through the sale of 3,773,585 shares of common stock and warrants to a single institutional investor. Each share is priced at $1.325, with warrants exercisable for five years at the same price. The closing of this deal is anticipated around April 25, 2022, pending customary conditions. Funds will be used for working capital and general corporate purposes.
Dermata Therapeutics (NASDAQ: DRMA; DRMAW) reported significant updates in its clinical trials and financial performance for FY 2021. The DMT310 Phase 2 trial for rosacea is over two-thirds enrolled, with topline results expected in H2 2022, while a Phase 2 trial for psoriasis is anticipated to start in H1 2022. The company ended 2021 with $10.8 million in cash, up from $0.5 million in 2020. R&D expenses rose to $3.5 million from $1.6 million, and general administrative expenses increased to $4.4 million from $1.6 million. Dermata aims for an End of Phase 2 meeting with the FDA in Q1 2023.
Dermata Therapeutics reported positive topline results from its DMT310 clinical trial for mild-to-moderate psoriasis, with 29.6% of patients achieving a PGA score of 0 or 1. The company successfully closed an upsized initial public offering (IPO) raising $18.0 million and appointed notable leaders to its Board and executive team. Dermata plans to present topline results from the DMT410 study on November 19, 2021, and initiate a Phase 2 study for DMT310 in rosacea in Q4 2021. As of September 30, 2021, Dermata had $12.6 million in cash, bolstered by its recent IPO.
Dermata Therapeutics (NASDAQ:DRMA)(NASDAQ:DRMAW) will present efficacy and safety data from a Phase 1b study evaluating DMT410 as a new topical delivery mechanism for botulinum toxin aimed at aesthetic skin conditions at the ASDS 2021 Annual Meeting on November 19-21, 2021. The study involved 10 patients receiving DMT410, comprising a topical application of Spongilla powder followed by botulinum toxin, with observed outcomes over 16 weeks. The presentation signifies Dermata's commitment to innovative treatments in dermatology.
Dermata Therapeutics (NASDAQ:DRMA, DRMAW) announced the appointment of Kyri Van Hoose as Senior Vice President and Chief Financial Officer, succeeding Thomas Insley, who will retire but remain as a financial consultant. With over 20 years of finance experience in the life sciences, Ms. Van Hoose aims to drive Dermata's growth and support development programs for DMT310 and DMT410. CEO Gerry Proehl expressed confidence in her ability to enhance corporate value and navigate the company’s future as a public entity.
Dermata Therapeutics has successfully completed its initial public offering, closing on the sale of 2,571,428 shares of common stock and accompanying warrants at $7.00 per share, raising approximately $18 million. The company intends to utilize the proceeds to further develop its clinical products, including DMT310 and DMT410, targeting conditions such as rosacea, psoriasis, and aesthetic indications. The offering included an option for underwriters to purchase additional shares, which has been partially exercised. Shares began trading on the Nasdaq under the symbols DRMA and DRMAW.